MMSI Filings — Merit Medical Systems Inc - FilingSpy
MMSI
Merit Medical Systems Inc
A maker of single-use medical devices for cardiology, radiology, oncology, and endoscopy, Merit Medical sells products like the SCOUT radar localization system, Wrapsody endoprosthesis, and C2 CryoBalloon. It was founded in 1987 in a Murray, Utah industrial park to replace fragile hospital glass syringes with a safer disposable plastic syringe—the name "Merit" reflects its performance-driven culture.
Gross margin crossed 51% for the first time in at least five years, lifted by a $6.9 million tariff refund.
reached a multi-year high, but the gain came from a one-time tariff refund rather than the core business. rose 9.5% to $418.8 million and rose 28.8% to $60.4 million, while SG&A continued to climb, reaching 30.9% of sales. The underlying cost trend did not improve, and the quarter's profitability was flattered by a non-recurring item.
Key takeaways
widened 3.1 points to 51.4%, the highest quarterly rate in the data provided, driven by a $6.9 million refund of previously paid recognized in cost of sales, along with higher sales volume and favorable product mix.
SG&A expense rose 14.3% to 30.9% of , up from 29.6% a year ago, as higher commissions, headcount additions, , and $5.6 million in costs from the View Point acquisition continued the upward trend that began in the second half of 2024.
Section summaries
Management's Discussion and Analysis
Q2 FY2026 sales rose 10% to $418.8M with gross margin up 320 bps to 51.4%, aided by $6.9M in IEEPA tariff refunds.
⌄
Total Q2 sales grew 9.5% to $418.8M, driven by 14.8% growth in Therapeutic (led by Cardiac Therapies, Endoscopy, and OEM) and 7.1% growth in Foundational (led by Vascular Intervention and Access).
expanded to 51.4% from 48.2%, primarily due to higher sales, favorable product mix, and a $6.9M refund of previously paid recognized in cost of sales.
increased 9.5% to $418.8 million, led by 14.8% growth in Therapeutic products — including Cardiac Therapies, Endoscopy, and OEM — and 7.1% growth in Foundational products.
Other expense rose to $9.1 million from $3.5 million, mainly due to a $5.1 million one-time charge for additional interest on the , which partially offset the gain and left up 19.1% at $38.8 million.
for the first half of fiscal 2026 was $110.0 million, down from $123.9 million a year earlier, as higher was more than offset by a $43.6 million build to support service levels and newly acquired products.
in the quarter fell 25.3% to $51.9 million, as the company spent $17.4 million on , part of the $80–$100 million planned for the full year including a new distribution facility.
What changed
The SG&A-to- ratio, flagged in every prior filing since Q3 2024 as a key watch item, rose further to 30.9% — the highest quarterly level in the data provided — as acquisition integration costs and headcount additions continued to outpace revenue growth.
reached 51.4%, but the 3.1-point expansion was driven by a $6.9 million IEEPA tariff refund; without it, the underlying margin would have been closer to the 48–49% range seen in recent quarters, suggesting the core profitability trend has not materially changed.
The CEO transition to Martha Aronson, flagged as a risk in FY2024 and FY2025 filings, has now been completed, and the Q2 2026 results show no disruption to growth, though SG&A costs remain elevated under the new leadership.
The Corporate Integrity Agreement with the Office of Inspector General, flagged as a regulatory overhang in every prior filing, expired in October 2025 and the company received formal completion notice in January 2026, removing that risk.
What to watch
Whether the SG&A-to- ratio, now at 30.9%, begins to decline in the second half of 2026 as View Point acquisition costs roll off and the Continued Growth Initiatives mature, or whether it remains elevated under the new CEO.
The trajectory of in Q3 2026, when the $6.9 million IEEPA tariff refund will not repeat, to see whether the underlying rate can hold above 48% or reverts toward the 47–48% range.
Whether the $43.6 million build in the first half of 2026 begins to unwind, which would provide a for after the 25.3% decline in Q2.
The impact of the U.S.-Israel-Iran conflict on resin and petroleum-based input costs, newly flagged as a risk factor, and whether it pressures in coming quarters.
SG&A expenses rose 14.3% to 30.9% of sales, driven by higher commissions, headcount additions, , and $5.6M in costs from the View Point acquisition.
Other expense increased to $9.1M from $3.5M, mainly due to a $5.1M one-time charge for additional interest on ; rose to $38.8M from $32.6M.
was $110.0M for H1 FY2026, down from $123.9M, as higher was offset by a $43.6M build to support service levels and newly acquired products.
Liquidity remains strong with $450.9M in cash and $697M in available borrowing capacity; for FY2026 is $80–$100M, including a new distribution facility.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and qualitative disclosures about currency exchange rate risk and interest rate risk are included in Part II, Item 7A "Quantitative and Qualitative Disclosures About Market Risk" in the 2025 Annual Report on Form 10-K. In the six-month period ended June 30, 2026, th…
⌄
Quantitative and qualitative disclosures about currency exchange rate risk and interest rate risk are included in Part II, Item 7A "Quantitative and Qualitative Disclosures About Market Risk" in the 2025 Annual Report on Form 10-K. In the six-month period ended June 30, 2026, there were no material changes from the information provided therein.
39
Table of Contents
See Note 10, Commitments and Contingencies set forth in the notes to our consolidated financial statements included in Part I, Item 1 of this report.
⌄
See Note 10, Commitments and Contingencies set forth in the notes to our consolidated financial statements included in Part I, Item 1 of this report.
Geopolitical conflict and restrictive debt covenants are the primary risks highlighted this quarter.
⌄
The U.S.-Israel-Iran conflict could disrupt energy supplies, raise resin and petroleum-based input costs, and weaken customer spending.
The Amended Fourth A&R Credit Agreement imposes restrictive and is secured by substantially all assets, risking acceleration and foreclosure upon default.
The $747.5M Convertible Senior Notes due 2029 carry that, if breached, could trigger acceleration, litigation, and immediate liquidity needs.
Increased borrowing capacity under the $700M may strain compliance with and reduce cash available for operations.